Effect of Chromium Weight Reduction on Adult Asthma Control (ECWAC)
This phase IV randomized controlled trial is designed to evaluate the effects of chromium picolinate supplementation in obese adults with stable asthma. A total of 60 participants will be recruited from Ain Shams University Hospitals and randomly assigned to receive either 400 mcg of chromium picolinate daily or a matching placebo for 12 weeks, in addition to standard asthma therapy.
The study aims to explore the interaction between metabolic dysfunction and asthma, as obesity-related asthma is often associated with systemic inflammation, insulin resistance, and dyslipidemia. These factors may contribute to poorer asthma control and impaired pulmonary function, and therefore represent potential targets for adjunctive therapeutic interventions such as chromium supplementation.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Study Design and Setting This study is a phase IV randomized controlled clinical trial (RCT) involving 60 adult patients diagnosed with asthma. Participants will be recruited from the outpatient clinic and pulmonary function unit of the Chest Department at Ain Shams University Hospitals.
Study Type: Phase IV randomized controlled clinical trial (RCT) Study Setting: Outpatient clinic and pulmonary function unit, Chest Department, Ain Shams University Hospitals Study Population: Adult patients with asthma, obesity, and diabetes mellitus
Sampling and Randomization Participants will be randomly assigned to study groups using computer-generated randomization sequences. Allocation concealment will be ensured through the use of sealed, opaque envelopes.
Ethical Considerations
The study protocol will be explained clearly to all eligible participants prior to enrollment.
The study will commence only after obtaining approval from the Ethical Committee of the Faculty of Medicine, Ain Shams University.
Written informed consent will be obtained from all participants prior to inclusion.
Participant safety will be prioritized, and all efforts will be made to minimize potential risks.
Confidentiality and anonymity of participant data will be strictly maintained. All participants will have an equal chance of being assigned to either study group.
No deceptive practices will be used during the study. Participants will have the right to withdraw from the study at any time without any consequences.
Study Procedures
All eligible participants will undergo the following assessments:
Demographic Data Collection: Age, sex, smoking status, and body mass index (BMI) Clinical Assessment: Detailed medical history including environmental exposures, potential risk factors, comorbidities, and duration of disease
Concomitant Care All participants will continue receiving standard asthma therapy throughout the study period.
Participants will be instructed to maintain a consistent intake of chromium-rich foods during the study to avoid dietary confounding.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Hieba Gamal Gamal Ezz El Regal, PhD
- Telefonnummer: +2 01002041611
- E-Mail: hiebagamal24@med.asu.edu.eg
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Age: 18-65 years
- Confirmed asthma diagnosis according to GINA criteria (7)
- Asthma stable for at least 4 weeks (no acute exacerbation)
- BMI of 30 kg/m² (obese category)
- Stable inhaled corticosteroid + LABA regimen in the last 4 weeks
- The patient is compliant on his asthma medication
- Willing and able to provide informed consent
- willing to continue in the study, follow investigator instructions
Exclusion Criteria:
- - Recent asthma exacerbation (within the last 4 weeks)
- Any change in asthma medications within 4 weeks
- renal or hepatic disease
- Use of lipid-lowering drugs or supplements in the past 3 months
- Use of Vitamin C, prostaglandin inhibitors, such as aspirin, oxalate, and antacids
- Current pregnancy or lactation
- Known allergy to chromium or adverse reaction to supplementation
- Participation in another interventional study in the past month
- History of heavy metal toxicity or chromium sensitivity
- Being on any weight control diet
- Being on a supplement containing chromium
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Kein Eingriff: Standard of Care
All participants continue standard asthma therapy and management - Study participants will be instructed to keep their dietary consumption of chromium rich foods constant all over the study period. |
|
|
Experimental: Chromium Picolinate
Two tablets collectively containing 400 mcg of Chromium picolinate which is equivalent to 49.4 mcg of elemental chromium. Taken once daily for 12 weeks. |
Two tablets collectively containing 400 mcg of Chromium picolinate which is equivalent to 49.4 mcg of elemental chromium. Taken once daily for 12 weeks. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in asthma control
Zeitfenster: from baseline to 12 weeks
|
Change in Asthma Control Test (ACT) Score (points; range 5-25)
|
from baseline to 12 weeks
|
|
Spirometry
Zeitfenster: from baseline to 12 weeks
|
Forced Expiratory Volume in 1 second (FEV₁) - L or % predicted
|
from baseline to 12 weeks
|
|
Frequency of rescue medication use
Zeitfenster: from baseline to 12 weeks
|
Frequency of Asthma Inhalers used
|
from baseline to 12 weeks
|
|
Asthma exacerbation frequency
Zeitfenster: from baseline to 12 weeks
|
Asthma exacerbation frequency
|
from baseline to 12 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Lipid Profile
Zeitfenster: From baseline to 12 weeks
|
Change in fasting total, HDL, LDL Cholesterol in addition to the triglycerides
|
From baseline to 12 weeks
|
|
Anthropometric Measurements
Zeitfenster: From baseline to 12 weeks
|
Change in Body Mass Index (BMI) Unit of Measure: kg/m²
|
From baseline to 12 weeks
|
|
Incidence of Treatment-Emergent Adverse Events
Zeitfenster: Monthly from baseline to 3 months
|
The outcome measure will assess the frequency of adverse effects occurring during the study period.
|
Monthly from baseline to 3 months
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Körpergewicht
- Erkrankungen des Immunsystems
- Erkrankungen der Atemwege
- Änderungen des Körpergewichts
- Lungenkrankheit
- Bronchialerkrankungen
- Lungenerkrankungen, obstruktive
- Überempfindlichkeit der Atemwege
- Überempfindlichkeit, sofort
- Überempfindlichkeit
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Gewichtsverlust
- Asthma
- Picolinsäure
Andere Studien-ID-Nummern
- FMASU R62/2026 (Registrierungskennung: Ain Shams Faculty of Medicine Institutional Review Board)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
- ANALYTIC_CODE
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .